ArticleNature communications2025
Engineered CRISPR-Cas9 for Streptomyces sp. genome editing to improve specialized metabolite production.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Review
- Unlocking the Bioactive Potential of Streptomyces: A Multidisciplinary Approach to Strain Improvement.MicrobiologyOpen · 2026Review
- Functional Engineering of Bioactive Peptides: Chemical Modifications and Synthetic Biology Approaches.International journal of molecular sciences · 2026Review
- Sustainable tea plantations: Harnessing chemical-microbial synergy and smart application triangulation for targeted weed control.Journal of advanced research · 2026Review
- Inducible CRISPRi enables efficient and high-fidelity genome editing in Streptomyces.Nucleic acids research · 2026Article
- CRISPR-Cas9-mediated construction of a Streptococcus agalactiae vaccine for tilapia and evaluation of its protective efficacy.BMC veterinary research · 2026Article
- Research and Application of the Polyene Macrolide Antibiotic Nystatin.Molecules (Basel, Switzerland) · 2026Review
- Productive chaos and precision engineering: decoupling discovery from manufacturing to revolutionize plant-inspired therapeutics.Frontiers in plant science · 2026Article
- Comparative genomics reveals hidden biosynthetic diversity inFrontiers in microbiology · 2026Article
- Species-specific alternative splicing of SP110 drives tuberculosis susceptibility in cattle.Veterinary research · 2025Article
- Enhancing conjugation from E. coli to Streptomyces coelicolor by incorporating traJ into mobilizable plasmids.Applied microbiology and biotechnology · 2025Article
- Identification of the orange pigment in Nonomuraea gerenzanensis and development of a pigment-free mutant.AMB Express · 2025Article
- Emerging strategies to enhance microbial natural product-based drug discovery.Current opinion in biotechnology · 2025Review
- Recent strategies and methodological advances for microbial natural product research in the post-genomics era.Archives of microbiology · 2025Review
- STAGE: A compact and versatile TnpB-based genome editing toolkit forProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Exploring pigment-producing Streptomyces as an alternative source to synthetic pigments: diversity, biosynthesis, and biotechnological applications. A review.World journal of microbiology & biotechnology · 2025Review
- Targeting Siderophore Biosynthesis to Thwart Microbial Growth.International journal of molecular sciences · 2025Review
- Engineering Useful Microbial Species for Pharmaceutical Applications.Microorganisms · 2025Review
- Coordinated regulation of propionyl-CoA carboxylase subunits drives precursor flux optimization in spinosad production.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The CRISPR-Cas9 system has frequently been used for genome editing in Streptomyces; however, cytotoxicity, caused by off-target cleavage, limits its application. In this study, we implement innovative modification to Cas9, strategically addressing challenges encountered during gene manipulation using Cas9 within strains possessing high GC content genome. The Cas9-BD, a modified Cas9 with the addition of polyaspartate to its N- and C-termini, is developed with decreased off-target binding and cytotoxicity compared with wild-type Cas9. Cas9-BD and similarly modified dCas9-BD have been successfully employed for simultaneous biosynthetic gene cluster (BGC) refactoring, multiple BGC deletions, or multiplexed gene expression modulations in Streptomyces. We also demonstrate improved secondary metabolite production using multiplexed genome editing with multiple single guide RNA libraries in several Streptomyces strains. Cas9-BD is also used to capture large BGCs using a developed in vivo cloning method. The modified CRISPR-Cas9 system is successfully applied to many Streptomyces sp., providing versatile and efficient genome editing tools for strain engineering of actinomycetes with high GC content genome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.